| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/15/2007 | US7217794 peptidomimetics and non-peptides that inhibit the activity of Factor XIa; purified human Factor XI protein mutants |
| 05/15/2007 | US7217792 an antibody reactive with the isolated polypeptide induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3; used to treat autoimmune diseases and allergic diseases |
| 05/15/2007 | US7217788 Controlling immunology; antiinflammatory agents |
| 05/15/2007 | US7217786 Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide |
| 05/15/2007 | US7217785 Genetic engineered apolipoproteins with phsophatide surface treatment; cardiovascular disorders, antiischemic agents, bone disorders, antiinflammatory agents |
| 05/15/2007 | US7217784 Polypeptide can be used for generating antibodies, detecting virus infection, and producing vaccines |
| 05/15/2007 | US7217770 Stable polymeric micelle-type drug composition and method for the preparation thereof |
| 05/15/2007 | US7217738 β2-adrenergic receptor agonists |
| 05/15/2007 | US7217733 Cardiovascular disorders; kidney disorders; antiinflammatory agents |
| 05/15/2007 | US7217730 Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus |
| 05/15/2007 | US7217700 Chemokines as adjuvants of immune response |
| 05/15/2007 | US7217694 Inhibitors of IAPP fibril formation and uses thereof |
| 05/15/2007 | US7217693 Human G protein-coupled receptor expressed in the dorsal root ganglia |
| 05/15/2007 | US7217692 Complex of a human FOXC2 protein and a FOXC2-interacting protein |
| 05/15/2007 | US7217691 Administering BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein is encoded by a nucleic acid |
| 05/15/2007 | US7217690 Administering to the mammal an effective amount of one or more cyclic peptides for treating a skin irritation |
| 05/15/2007 | US7217689 For increasing hematocrit in a patient |
| 05/15/2007 | US7217687 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 05/15/2007 | US7217686 DNA sequence encoding oncofetal ferritin protein |
| 05/15/2007 | US7217572 Modulation of HIF1α and HIF2α expression |
| 05/15/2007 | US7217555 isolated human NAALAD-ase (N-acetylated alpha-linked acidic dipeptidases) L protein; |
| 05/15/2007 | US7217554 Proteases and variants thereof |
| 05/15/2007 | US7217547 Aspartoacylase gene, protein, and methods of screening for mutations associated with Canavan disease |
| 05/15/2007 | US7217539 Cell death inducers for mast cells |
| 05/15/2007 | US7217535 Immunoassay diagnosis of susceptibility to atherosclerosis by analyzing blood for presence of enzyme using polyclonal or monoclonal antibodies; elevated levels are indicative of susceptibility |
| 05/15/2007 | US7217529 antibody binds to polypeptide which is a member of the chemokine family; diagnostic methods for detecting disorders related to the immune system |
| 05/15/2007 | US7217528 isolated antibody that specifically binds to polypeptides for diagnosing, preventing and treating autoimmune, cancer and transplant disorders; wound healing agents |
| 05/15/2007 | US7217526 identifying T cells in a sample that become activated in the presence of a vaccinia or variola virus using immunogenic mutant or fragment of peptide 165 as a CD8 T cell epitope |
| 05/15/2007 | US7217524 Method for diagnosing aplasia of corpus callosum |
| 05/15/2007 | US7217416 Use of gamma globulin for the topical treatment of lesions of dermatitis |
| 05/15/2007 | US7217415 NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use |
| 05/15/2007 | US7217413 Use of novel agents inducing cell death in synergy with interferons |
| 05/15/2007 | US7217412 IL-17C related mammalian cytokine polypeptides |
| 05/15/2007 | CA2515166C Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome |
| 05/15/2007 | CA2324649C Human p51 genes and gene products thereof |
| 05/15/2007 | CA2294337C Preparation of pharmaceutical compositions |
| 05/15/2007 | CA2266811C Method and composition for wound treatment |
| 05/15/2007 | CA2255540C Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/15/2007 | CA2176948C Chaperonin 10 |
| 05/15/2007 | CA2159822C Process for inhibiting the transcription of genes |
| 05/15/2007 | CA2149922C Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| 05/15/2007 | CA2130452C Altered antibodies, products and processes relating thereto |
| 05/15/2007 | CA2094705C Pharmaceutical composition for treating or preventing malign tumors |
| 05/15/2007 | CA2071879C Glutamate receptor compositions and methods |
| 05/15/2007 | CA2065414C Treatment of autoimmune disease |
| 05/15/2007 | CA2011633C Intercellular adhesion molecule - 2 and its binding ligands |
| 05/10/2007 | WO2007053810A2 Liposomally encapsulated reduced glutathione, including with other pharmacologic preparation, capable of administration as an oral, topical, intraoral or transmucosal, preparation, for reversal and prevention of oxidation of cholesterol and of low density lipoprotein |
| 05/10/2007 | WO2007053792A2 Improving the pharmacokinetics of protease inhibitors and other drugs |
| 05/10/2007 | WO2007053729A2 High load particles for inhalation having rapid release properties |
| 05/10/2007 | WO2007053619A2 A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency |
| 05/10/2007 | WO2007053577A2 Compositions and methods for diagnosing and treating cancer |
| 05/10/2007 | WO2007053574A2 Combinations comprising sorafenib and interferon for the treatment of cancer |
| 05/10/2007 | WO2007053558A2 Vancomycin formulations having reduced amount of histamine |
| 05/10/2007 | WO2007053533A2 Sodium chloride solution for drug reconstitution or dilution |
| 05/10/2007 | WO2007053512A2 Novel protein transduction domains and uses therefor |
| 05/10/2007 | WO2007053455A2 Polypeptide ligans for toll-like receptor 4 (tlr4) |
| 05/10/2007 | WO2007052854A1 Use of the gonadotropin-releasing hormone ii antagonists and its analogues |
| 05/10/2007 | WO2007052841A1 Platelet aggregation inhibitor composition |
| 05/10/2007 | WO2007052641A1 Intestinal immunity activator |
| 05/10/2007 | WO2007052561A1 Method for prevention of myocardial hypertrophy by inhibiting interaction between slim1 and usp, and agent for prevention of myocardial hypertrophy |
| 05/10/2007 | WO2007052326A2 Method for conversion of uric acid to allantoin and related enzymes |
| 05/10/2007 | WO2007052067A2 Von willebrand factor (vwf) binding peptides |
| 05/10/2007 | WO2007051987A1 Insulinotropic compounds and uses thereof |
| 05/10/2007 | WO2007051975A2 Compositions comprising igbpma and uses thereof |
| 05/10/2007 | WO2007051898A1 Alternative oxidase and uses thereof |
| 05/10/2007 | WO2007051836A2 Compositions for treating dermatological and neurological disorders |
| 05/10/2007 | WO2007051781A1 Novel cxc-chemokine antagonists |
| 05/10/2007 | WO2007051641A1 Use of calcitonin for the treatment of ra |
| 05/10/2007 | WO2007051550A1 Oligopeptides and their use |
| 05/10/2007 | WO2007051431A2 Stable formulations containing enhancing proportions of gamma- and alpha-interferons |
| 05/10/2007 | WO2007051317A1 Compositions and methods for treating atherosclerosis |
| 05/10/2007 | WO2007051316A1 Inhibition of autophagy genes in cancer chemotherapy |
| 05/10/2007 | WO2007031574A3 Therapeutic use of outer shigella protein f (os pf) |
| 05/10/2007 | WO2007029041A3 Interferon lambda therapy for treatment of respiratory diseases |
| 05/10/2007 | WO2007027092A3 Oral composition for moisturising skin |
| 05/10/2007 | WO2007025991A3 Treatment of optic neuritis |
| 05/10/2007 | WO2007023479A3 Treatment of central nervous system injury |
| 05/10/2007 | WO2007022515A9 Stem cell derived factors for treating pathologic conditions |
| 05/10/2007 | WO2007020260A3 Pancreatin micropellet cores suitable for enteric coating |
| 05/10/2007 | WO2007020259A3 Controlled release pharmaceutical compositions for acid labile drugs |
| 05/10/2007 | WO2007018564A3 Enhancement of b cell proliferation by il-15 |
| 05/10/2007 | WO2007006751A3 Use of bpi protein for the treatment of disorders of the metabolism and cardiovascular disorders |
| 05/10/2007 | WO2007005672A3 Treatment and prevention of respiratory diseases and conditions |
| 05/10/2007 | WO2007004526A3 Identification of compounds modulating the smyd3 transferase for the treatment of cancer |
| 05/10/2007 | WO2006134601A3 Methods for the treatment of renal failure |
| 05/10/2007 | WO2006132445A3 A pharmaceutical composition for treating and diagnosing a disorder associated with peroxisomal biogenesis and function |
| 05/10/2007 | WO2006131512A3 Anti-thrombotic agents |
| 05/10/2007 | WO2006129095A3 Sustained release preparations of pro-insulin c-peptide |
| 05/10/2007 | WO2006126982A3 Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases |
| 05/10/2007 | WO2006123164A3 Lps-binding and bactericidal cytokines and interferons |
| 05/10/2007 | WO2006117694A3 Genetically encoded photosensitizers and methods for using same |
| 05/10/2007 | WO2006114387A3 Insp163 polypeptides for the treatment or prevention of cancer and arthritis |
| 05/10/2007 | WO2006101503A3 Method for screening agents against human prostate disease |
| 05/10/2007 | WO2006067163A3 Blood pressure lowering oligopeptides in a single enzymatic step |
| 05/10/2007 | WO2006050247A3 Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| 05/10/2007 | WO2006039326A3 Inhibitors of hepatitits c virus |
| 05/10/2007 | WO2005069750A3 Therapeutic composition with nanoscale activation agents |
| 05/10/2007 | WO2005037221A3 Cystatin c as an antagonist of tgf-b and methods related thereto |
| 05/10/2007 | WO2004110337A3 Cell permeable conjugates of peptides for inhibition of protein kinases |
| 05/10/2007 | WO2004060910A3 Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20 |